- León-Mimila, P;
- Villamil-Ramírez, H;
- Li, XS;
- Shih, DM;
- Hui, ST;
- Ocampo-Medina, E;
- López-Contreras, B;
- Morán-Ramos, S;
- Olivares-Arevalo, M;
- Grandini-Rosales, P;
- Macías-Kauffer, L;
- González-González, I;
- Hernández-Pando, R;
- Gómez-Pérez, F;
- Campos-Pérez, F;
- Aguilar-Salinas, C;
- Larrieta-Carrasco, E;
- Villarreal-Molina, T;
- Wang, Z;
- Lusis, AJ;
- Hazen, SL;
- Huertas-Vazquez, A;
- Canizales-Quinteros, S
Aims
Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). These associations could be mediated by insulin resistance. However, the relationships among these metabolites, insulin resistance and NAFLD have not been thoroughly investigated. Moreover, it has recently been suggested that TMAO could play a role in NAFLD by altering bile acid metabolism. We examined the association between circulating TMAO, choline and betaine levels and NAFLD in obese subjects.Methods
Serum TMAO, choline, betaine and bile acid levels were measured in 357 Mexican obese patients with different grades of NAFLD as determined by liver histology. Associations of NAFLD with TMAO, choline and betaine levels were tested. Moreover, association of TMAO levels with non-alcoholic steatohepatitis (NASH) was tested separately in patients with and without T2D.Results
TMAO and choline levels were significantly associated with NAFLD histologic features and NASH risk. While increased serum TMAO levels were significantly associated with NASH in patients with T2D, in non-T2D subjects this association lost significance after adjusting for sex, BMI and HOMA2-IR. Moreover, circulating secondary bile acids were associated both with increased TMAO levels and NASH.Conclusions
In obese patients, circulating TMAO levels were associated with NASH mainly in the presence of T2D. Functional studies are required to evaluate the role of insulin resistance and T2D in this association, both highly prevalent in NASH patients.